1994
Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
Longo D, Duffey P, Jaffe E, Raffeld M, Hubbard S, Fisher R, Wittes R, DeVita V, Young R. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy. Journal Of Clinical Oncology 1994, 12: 2153-9. PMID: 7523607, DOI: 10.1200/jco.1994.12.10.2153.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinCombined Modality TherapyCyclophosphamideCytarabineDisease-Free SurvivalDoxorubicinEtoposideFemaleFollow-Up StudiesHumansLymphoma, Non-HodgkinMaleMechlorethamineMethotrexateMiddle AgedPrednisoneProcarbazinePrognosisRemission InductionSurvival RateVincristineConceptsAdvanced stage diseaseProMACE-MOPPProMACE-CytaBOMBurkitt's lymphomaLocalized diseaseComplete responseInvolved-field radiation therapyCombination chemotherapy programsOverall survival rateEfficacy of cyclophosphamideTreatment of patientsHigh-grade lymphomaMedian followComplete remissionIntercurrent illnessAdult patientsChemotherapy programCombination chemotherapyOverall survivalAggressive lymphomaRadiation therapyPatientsLymphomaSurvival rateDisease
1985
ProMACE-MOPP combination chemotherapy for diffuse lymphomas.
Fisher R, Young R, Longo D, DeVita V. ProMACE-MOPP combination chemotherapy for diffuse lymphomas. Seminars In Oncology 1985, 12: 29-32. PMID: 2579441.Peer-Reviewed Original ResearchConceptsComplete remissionCombination chemotherapyAdvanced stageComplete response rateLong-term survivalMOPP combination chemotherapyC-MOPPComplete respondersNew regimenHodgkin's lymphomaBurkitt's lymphomaDiffuse lymphomaResponse rateFatal diseaseLymphomaPatientsDeath rateNCI studyHigh gradeRemissionChemotherapyDiseaseLarge cellsMyelosuppressionRegimenTreatment of diffuse large cell non-Hodgkin’s lymphomas
Fisher R, Devita V, Longo D, Ihde D, Young R. Treatment of diffuse large cell non-Hodgkin’s lymphomas. Developments In Oncology 1985, 465-469. DOI: 10.1007/978-1-4613-2607-6_49.Peer-Reviewed Original ResearchLong-term disease-free survivalDisease-free survivalAdvanced stageAdvanced diffuse histiocytic lymphomaDiffuse mixed lymphomaDiffuse histiocytic lymphomaDiffuse large cellDiffuse aggressive lymphomasLarge cell lymphomaComplete remissionComplete respondersCombination chemotherapyMixed lymphomaAggressive lymphomaHodgkin's lymphomaHistiocytic lymphomaTherapeutic resultsCell lymphomaBurkitt's lymphomaLymphomaFatal diseaseTreatment programPatientsSurvivalLarge cells
1982
Malignant lymphoma I. The histology and staging of 473 patients at the national cancer institute
Anderson T, Chabner B, Young R, Berard C, Garvin AJ, Simon R, Devita V. Malignant lymphoma I. The histology and staging of 473 patients at the national cancer institute. Cancer 1982, 50: 2699-2707. PMID: 7139563, DOI: 10.1002/1097-0142(19821215)50:12<2699::aid-cncr2820501202>3.0.co;2-a.Peer-Reviewed Original ResearchConceptsDiffuse lymphoma patientsNodular lymphoma patientsLymphoma patientsNational Cancer InstituteDiffuse lymphomaCancer InstituteCS III diseaseAdvanced-stage patientsBurkitt's lymphoma patientsExtranodal diseaseClinical stagingConsecutive patientsMedian agePathologic stagingStage patientsRetrospective reviewMalignant lymphomaNodular lymphomaSystemic symptomsRappaport systemPathologic materialBurkitt's lymphomaPatientsLymphomaDiseaseUndifferentiated non‐Hodgkin'S lymphomas (Burkitt's and non‐Burkitt's types). The relevance of making this histologic distinction
Miliauskas J, Berard C, Young R, Garvin A, Edwards B, Devita V. Undifferentiated non‐Hodgkin'S lymphomas (Burkitt's and non‐Burkitt's types). The relevance of making this histologic distinction. Cancer 1982, 50: 2115-2121. PMID: 7127252, DOI: 10.1002/1097-0142(19821115)50:10<2115::aid-cncr2820501024>3.0.co;2-9.Peer-Reviewed Original ResearchConceptsBurkitt's lymphomaMedian ageStage IVPrimary siteHistologic distinctionIntra-abdominal involvementFive-year survivalNational Cancer InstituteMedian survivalBurkitt's typeRetrospective studyHodgkin's lymphomaPatient populationLonger survivalCancer InstituteLymphomaPatientsSurvivalDiseaseMonthsAgePresentationYearsCases
1976
Combined modality treatment of American Burkittapos;s lymphoma
Ziegler J, Devita V, Graw R, Herzig G, Leventhal B, Levine A, Pomeroy T. Combined modality treatment of American Burkittapos;s lymphoma. Cancer 1976, 38: 2225-2231. PMID: 1036716, DOI: 10.1002/1097-0142(197612)38:6<2225::aid-cncr2820380606>3.0.co;2-f.Peer-Reviewed Original ResearchConceptsBurkitt's lymphomaCombined modality treatmentBone marrow autograftsMajor therapeutic goalPrevention of relapseThird remissionFirst remissionIntensive chemotherapyComplete responseModality treatmentInitial treatmentAmerican patientsMarrow autograftsRisk factorsClinical trialsTherapeutic goalsPatientsLymphomaRemissionChemotherapyTreatmentImmunotherapyRelapseRadiotherapyAutograft
1975
The American Burkitt Lymphoma Registry: a progress report.
Levine P, Connelly R, Berard C, O'Connor G, Dorfman R, EASTON J, DeVita V. The American Burkitt Lymphoma Registry: a progress report. Annals Of Internal Medicine 1975, 83: 31-6. PMID: 1147436, DOI: 10.7326/0003-4819-83-1-31.Peer-Reviewed Original ResearchConceptsLymphoma RegistryAfrican patientsAmerican patientsBurkitt's lymphomaEpstein-Barr virus titersPeripheral lymph node involvementAbrupt clinical presentationEpstein-Barr virus genomeHigh-dose cyclophosphamideLymph node involvementAmerican Burkitt's lymphomaCentral nervous systemPredominance of menPathologic reviewClinical presentationLymphocytic lymphomaAbsence of casesNonendemic regionsGastrointestinal tractNervous systemLymphomaPatientsVirus titersMore casesTime-space clusteringAmerican Burkitt's lymphoma: A clinicopathologic study of 30 cases I. Clinical factors relating to prolonged survival
Arseneau J, Canellos G, Banks P, Berard C, Gralnick H, DeVita V. American Burkitt's lymphoma: A clinicopathologic study of 30 cases I. Clinical factors relating to prolonged survival. The American Journal Of Medicine 1975, 58: 314-321. PMID: 1115074, DOI: 10.1016/0002-9343(75)90597-5.Peer-Reviewed Original ResearchConceptsLDH levelsTumor massComplete remissionIU/Central nervous system involvementSerum lactic dehydrogenase levelsMonths of treatmentNervous system involvementSerum LDH levelsAmerican Burkitt's lymphomaResults of therapyLactic dehydrogenase levelsLarge tumor massParenteral cyclophosphamideClinical characteristicsClinicopathologic studyLocalized diseaseClinical factorsComplete responseFrequent siteSystem involvementTumor regressionDehydrogenase levelsSudden deathBurkitt's lymphoma
1974
Clinical antitumor activity and toxicity of streptozotocin (NSC‐85998)
Schein P, O'Connell M, Blom J, Hubbard S, Magrath I, Bergevin P, Wiernik P, Ziegler J, Devita V. Clinical antitumor activity and toxicity of streptozotocin (NSC‐85998). Cancer 1974, 34: 993-1000. PMID: 4371075, DOI: 10.1002/1097-0142(197410)34:4<993::aid-cncr2820340404>3.0.co;2-t.Peer-Reviewed Original ResearchConceptsMalignant carcinoid tumorsNormal renal functionIslet cell carcinomaClinical antitumor activityAcute lymphocytic leukemiaToxicity of streptozotocinHematologic toxicityAdvanced malignanciesRenal damageRenal functionCarcinoid tumorsHodgkin's diseaseCell carcinomaLymphocytic lymphomaTherapeutic responseLymphocytic leukemiaTumor massBurkitt's lymphomaDrug effectsMaximum dosesPatientsTotal doseStreptozotocinLymphomaAntitumor activity